Cite
EE447 Budget Impact Analysis of Tepotinib in England for Patients With Advanced Non-Small Cell Lung Cancer (aNSCLC) Harboring MET Exon 14 (METex14) Skipping.
MLA
McLean, T., et al. “EE447 Budget Impact Analysis of Tepotinib in England for Patients With Advanced Non-Small Cell Lung Cancer (ANSCLC) Harboring MET Exon 14 (METex14) Skipping.” Value in Health, vol. 25, no. 12, Dec. 2022, p. S143. EBSCOhost, https://doi.org/10.1016/j.jval.2022.09.692.
APA
McLean, T., Alexopoulos, S., Hook, E., Batteson, R., & Vioix, H. (2022). EE447 Budget Impact Analysis of Tepotinib in England for Patients With Advanced Non-Small Cell Lung Cancer (aNSCLC) Harboring MET Exon 14 (METex14) Skipping. Value in Health, 25(12), S143. https://doi.org/10.1016/j.jval.2022.09.692
Chicago
McLean, T, S Alexopoulos, E Hook, R Batteson, and H Vioix. 2022. “EE447 Budget Impact Analysis of Tepotinib in England for Patients With Advanced Non-Small Cell Lung Cancer (ANSCLC) Harboring MET Exon 14 (METex14) Skipping.” Value in Health 25 (12): S143. doi:10.1016/j.jval.2022.09.692.